NasdaqGS - Nasdaq Real Time Price USD

Repligen Corporation (RGEN)

127.52

-3.78

(-2.88%)

At close: June 13 at 4:00:00 PM EDT

125.00

-2.52

(-1.98%)

After hours: June 13 at 5:17:27 PM EDT

1 Unprofitable Stock for Long-Term Investors and 2 to Ignore

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

StockStory 4 days ago

RGEN
-2.88%

WBTN

SRPT
Three Stocks That May Be Trading Below Their Intrinsic Value In June 2025

The United States market has experienced a steady climb, rising 1.4% in the last week and showing a robust 12% increase over the past year, with earnings projected to grow by 15% annually. In this environment, identifying stocks that may be trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervalued assets amidst positive market momentum.

Simply Wall St. 8 days ago

DAY

RDDT

RGEN
-2.88%
Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services Stocks

Let’s dig into the relative performance of Repligen (NASDAQ:RGEN) and its peers as we unravel the now-completed Q1 drug development inputs & services earnings season.

StockStory 9 days ago

RGEN
-2.88%

UFPT

IQV
Drug Development Inputs & Services Stocks Q1 In Review: Repligen (NASDAQ:RGEN) Vs Peers

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Repligen (NASDAQ:RGEN) and the best and worst performers in the drug development inputs & services industry.

StockStory 10 days ago

RGEN
-2.88%

UFPT

CRL
Do Options Traders Know Something About Repligen (RGEN) Stock We Don't?

Investors need to pay close attention to Repligen (RGEN) stock based on the movements in the options market lately.

Zacks 11 days ago

RGEN
-2.88%
3 of Wall Street’s Favorite Stocks in Hot Water

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

StockStory 12 days ago

RGEN
-2.88%
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 15 days ago

RGEN
-2.88%

GILD
Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report

WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Report and related reporting framework disclosures. Themed “Perspectives on Progress”, this report communicates the company’s progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Commu

GlobeNewswire 17 days ago

RGEN
-2.88%
Repligen Corporation to Present at William Blair Growth Conference

WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45th Annual Growth Stock Conference being held June 3 – 5 in Chicago. Olivier Loeillot, President and Chief Executive Officer is scheduled to present a company overview on June 3rd at 1:20 p.m. CT. A live webcast of the conference presentation will be accessible through Repli

GlobeNewswire 22 days ago

RGEN
-2.88%
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know

A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains.

StockStory last month

BRKR

A

RGEN
-2.88%
1 High-Flying Stock with Exciting Potential and 2 to Keep Off Your Radar

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.

StockStory last month

RGEN
-2.88%

NOW
Repligen Corporation to Present at Upcoming May Investor Conferences

WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences. RBC Capital Markets’ 2025 Global Healthcare Conference, being held in New York on May 20-21. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 20 at 3:35 p.m. ET, in addition to a series of one-on-

GlobeNewswire last month

RGEN
-2.88%
QGEN or RGEN: Which Is the Better Value Stock Right Now?

QGEN vs. RGEN: Which Stock Is the Better Value Option?

Zacks last month

RGEN
-2.88%

QGEN
Repligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On Healthcare

Conestoga Capital Advisors, an asset management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets started the year with a rally due to optimism about a strong economy and expectations of moderating inflation and lower interest rates. However, concerns over slowing earnings from major Technology companies, geopolitical […]

Insider Monkey last month

RGEN
-2.88%

^RUT
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’

We recently published an article titled Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment to highlight the top-performing stocks since […]

Insider Monkey last month

REGN

RGEN
-2.88%
Jim Cramer on Repligen Corporation (RGEN): ‘I’m Not Quite Ready to Stick My Neck Out on This One’

We recently published an article titled Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years. In this article, we are going to take a look at where Repligen Corporation (NASDAQ:RGEN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment to highlight the top-performing stocks since the […]

Insider Monkey last month

RGEN
-2.88%
RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 10.4% year on year to $169.2 million. The company’s full-year revenue guidance of $707.5 million at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $0.39 per share was 11.4% above analysts’ consensus estimates.

StockStory last month

RGEN
-2.88%
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y

RGEN reports better-than-expected first-quarter results. The company increases its total revenue (on a reported basis) guidance for 2025.

Zacks last month

RGEN
-2.88%
Repligen Corp (RGEN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Repligen Corp (RGEN) reports a robust start to 2025 with significant organic growth and strategic advancements despite regional challenges.

GuruFocus.com last month

RGEN
-2.88%
Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 11.43% and 2.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

RGEN
-2.88%

Performance Overview

Return	RGEN	S&P 500 (^GSPC)
YTD	-11.41%	+1.62%
1-Year	+1.25%	+10.00%
3-Year	-9.35%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Repligen Corporation (RGEN)

1 Unprofitable Stock for Long-Term Investors and 2 to Ignore

Three Stocks That May Be Trading Below Their Intrinsic Value In June 2025

Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services Stocks

Drug Development Inputs & Services Stocks Q1 In Review: Repligen (NASDAQ:RGEN) Vs Peers

Do Options Traders Know Something About Repligen (RGEN) Stock We Don't?

3 of Wall Street’s Favorite Stocks in Hot Water

Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?

Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report

Repligen Corporation to Present at William Blair Growth Conference

Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know

1 High-Flying Stock with Exciting Potential and 2 to Keep Off Your Radar

Repligen Corporation to Present at Upcoming May Investor Conferences

QGEN or RGEN: Which Is the Better Value Stock Right Now?

Repligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On Healthcare

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’

Jim Cramer on Repligen Corporation (RGEN): ‘I’m Not Quite Ready to Stick My Neck Out on This One’

RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty

Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y

Repligen Corp (RGEN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates

Performance Overview